Advances in Clinical and Experimental Medicine

Adv Clin Exp Med
Impact Factor (IF) – 1.514
Index Copernicus (ICV 2018) – 157.72
MNiSW – 40
Average rejection rate – 84.38%
ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download PDF

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 3, March, p. 385–390

doi: 10.17219/acem/90771

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Creative Commons BY-NC-ND 3.0 Open Access

Expression of the PIM2 gene is associated with more aggressive clinical course in patients with chronic lymphocytic leukemia

Katarzyna Kapelko-Słowik1,A,B,C,D,E,F, Jarosław Dybko1,B,E, Krzysztof Grzymajło2,B,C,D, Bożena Jaźwiec1,B,C, Donata Urbaniak-Kujda1,A,B,C,D, Mirosław Słowik3,B,C,D, Stanisław Potoczek1,B,C, Dariusz Wołowiec1,A,C,E,F

1 Department of Hematology, Neoplastic Blood Disorders and Bone Marrow Transplantation, Wroclaw Medical University, Poland

2 Department of Biochemistry, Pharmacology and Toxicology, Wrocław University of Environmental and Life Sciences, Poland

3 Department of Ophthalmology, Wroclaw Medical University, Poland

Abstract

Background. The PIM2 gene belongs to the PIM family, which encodes serine/threonine kinases involved in cell survival and apoptosis. The relation between the expression of the PIM2 gene and the course of chronic lymphocytic leukemia (CLL) has not been fully determined.
Objectives. The aim of the study was to evaluate the role of the PIM2 gene as a marker of CLL malignancy and its importance as a predictive and prognostic factor.
Material and Methods. Sixty-seven patients, 35 females and 32 males, aged 49–90 years, with de novo CLL, and 14 healthy individuals were enrolled in the study. Expression of the PIM2 gene was analyzed using TaqMan RQ-PCR assay and western blot test.
Results. Median PIM2 gene expression in CLL patients was higher than in controls. Patients with high expression of the PIM2 gene had shorter progression-free survival and time to first treatment than patients with low PIM2 expression. It was found that patients with CR had lower expression of the PIM2 gene than patients without complete remission (CR). Notably, associations between high PIM2 expression and rapid lymphocyte doubling time, the percentage of malignant lymphocytes with ZAP70 expression and the Rai stage were revealed.
Conclusion. We found that the PIM2 gene is associated with a more aggressive clinical course of CLL.

Key words

PIM2 gene, chronic lymphocytic leukemia, prognostic factor

References (24)

  1. Breuer ML, Cuypers HT, Berns A. Evidence for the involvement of Pim-2, a new common proviral insertion site, in progression of lymphomas. EMBO J. 1989;8(3):743–748.
  2. Baytel D, Shalom S, Madgar I, et al. The human Pim-2 proto-oncogene and its testicular expression. Biochim Biophys Acta. 1998;1442(2–3):274–285.
  3. Mikkers H, Allen J, Knipscheer P, et al. High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat Genet. 2002;32(1):153–159. Erratum in: Nat Genet. 2002;32(3):459.
  4. Fox CJ, Hammerman PS, Cinalli RM, et al. The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev. 2003;17(15):1841–1854.
  5. Nawijn MC, Alendar A, Berns A. For better or for worse: The role of Pim oncogenes in tumorigenesis. Nat Rev Cancer. 2011;11:23–34.
  6. Kapelko-Słowik K, Owczarek TB, Grzymajło K, et al. Elevated PIM2 gene expression is associated with poor survival of patients with acute myeloid leukemia. Leuk Lymphoma. 2016;57(9):2140–2149.
  7. Decker S, Finter J, Forde AJ, et al. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1). Mol Cancer Ther. 2014;13:1231–1245.
  8. Martín-Sánchez E, Odqvist L, Rodríguez-Pinilla SM, et al. PIM kinases as potential therapeutic targets in a subset of peripheral T cell lymphoma cases. PLOS ONE. 2014;9:e112148.
  9. Asano J, Nakano A, Oda A, et al. The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells. Leukemia. 2011;25:1182–1188.
  10. Cohen AM, Grinblat B, Bessler H, et al. Increased expression of the hPim-2 gene in human chronic lymphocytic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma. 2004;45(5):951–955.
  11. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–5456.
  12. Eichhorst B, Robak T, Montserrat E, et al. ESMO Guidelines Committee. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v78–84.
  13. Narlik-Grassow M, Blanco-Aparicio C, Carnero A. The PIM family of serine/threonine kinases in cancer. Med Res Rev. 2014;34:136–159.
  14. Brault L, Gasser C, Bracher F, et al. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica. 2010;95(6):1004–1015.
  15. Kapelko-Słowik K, Urbaniak-Kujda D, Wołowiec D, et al. Expression of PIM-2 and NF-κB genes is increased in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and is associated with complete remission rate and overall survival. Postepy Hig Med Dosw. 2013;67:553–559.
  16. Tam CS, Seymour JF, Roberts AW. Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia. Semin Oncol. 2016;43(2):274–279.
  17. Chen LS, Redkar S, Bearss D, et al. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 2009;114(19):4150–4157.
  18. Gómez-Abad C, Pisonero H, Blanco-Aparicio C, et al. PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma. Blood. 2011;118:5517–5527.
  19. Garcia PD, Langowski JL, Wang Y, et al. Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers. Clin Cancer Res. 2014;20:1834–1845.
  20. Hammerman PS, Fox CJ, Birnbaum MJ, et al. Pim and Akt oncogenes are independent regulators of haematopoietic cell growth and survival. Blood. 2005;105(11):4477–4483.
  21. Hammerman PS, Fox C, Cinalli R, et al. Lymphocyte transformation by Pim-2 is dependent on nuclear factor-κB activation. Cancer Res. 2004;64:8341–8348.
  22. Hüttmann A, Klein-Hitpass L, Thomale J, et al. Gene expression signatures separate B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 expression status. Leukemia. 2006;20:1774–1782.
  23. Swords R, Kelly K, Carew J, et al. The Pim kinases: New targets for drug development. Curr Drug Targets. 2011;12(14):2059–2066.
  24. Tamburini J, Green AS, Bardet V, et al. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood. 2009;114(8):1618–1627.